Corient Private Wealth LLC Sells 23,538 Shares of The Cooper Companies, Inc. (NASDAQ:COO)

Corient Private Wealth LLC decreased its stake in The Cooper Companies, Inc. (NASDAQ:COO) by 19.4% during the 4th quarter, HoldingsChannel.com reports. The fund owned 97,605 shares of the medical device company’s stock after selling 23,538 shares during the period. Corient Private Wealth LLC’s holdings in Cooper Companies were worth $8,973,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new position in shares of Cooper Companies during the 4th quarter worth $691,000. Highland Capital Management LLC purchased a new position in shares of Cooper Companies in the fourth quarter worth about $4,004,000. Caprock Group LLC bought a new stake in shares of Cooper Companies in the fourth quarter valued at approximately $282,000. Franklin Resources Inc. lifted its stake in shares of Cooper Companies by 194.0% during the 3rd quarter. Franklin Resources Inc. now owns 48,892 shares of the medical device company’s stock valued at $5,265,000 after buying an additional 32,260 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its holdings in Cooper Companies by 6.6% in the 3rd quarter. Principal Financial Group Inc. now owns 238,305 shares of the medical device company’s stock worth $26,295,000 after buying an additional 14,687 shares during the period. 24.39% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on COO shares. Needham & Company LLC reissued a “hold” rating on shares of Cooper Companies in a report on Friday, March 7th. Stifel Nicolaus dropped their price objective on Cooper Companies from $115.00 to $105.00 and set a “buy” rating on the stock in a report on Friday, March 7th. Robert W. Baird reduced their target price on Cooper Companies from $117.00 to $107.00 and set an “outperform” rating for the company in a report on Friday, March 7th. BNP Paribas raised shares of Cooper Companies to a “hold” rating in a report on Thursday, March 13th. Finally, Morgan Stanley decreased their target price on shares of Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating on the stock in a report on Friday, December 6th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $110.25.

Cooper Companies Price Performance

Shares of NASDAQ:COO opened at $80.39 on Friday. The company’s fifty day moving average price is $90.22 and its 200-day moving average price is $98.31. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.91 and a quick ratio of 1.12. The firm has a market capitalization of $16.08 billion, a price-to-earnings ratio of 41.23, a PEG ratio of 2.25 and a beta of 1.02. The Cooper Companies, Inc. has a one year low of $77.05 and a one year high of $112.38.

Cooper Companies (NASDAQ:COO) last released its earnings results on Thursday, March 6th. The medical device company reported $0.92 EPS for the quarter, meeting analysts’ consensus estimates of $0.92. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The business had revenue of $964.70 million for the quarter, compared to analysts’ expectations of $981.25 million. On average, equities research analysts anticipate that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.